Robert Lewis
Chief Executive Officer & Co-Founder NOK Therapeutics
Mr. Lewis has served as CEO and Director of NOK Therapeutics since June 2024, bringing over 30 years of leadership experience in the biotechnology and pharmaceutical sectors. His career began at TEVA Pharmaceuticals and advanced through executive roles at Sigma and Cypress Pharmaceuticals. Rob has overseen departments spanning Scientific, Medical, Regulatory, and Clinical Affairs, as well as Business Development, and has led more than 30 NDA and ANDA drug approvals. Since 2012, he has founded and held ownership positions in multiple biotech and medical device companies. He earned his B.S. in Chemistry and Biology from Columbia College.
Seminars
- Sustained Long-Term Survival: Extended follow-up demonstrates significant overall survival benefit signal in ASCT eligible multiple myeloma cohorts
- Clinical Durability in High-Risk Populations: Notably, high-risk cytogenetic features by FISH achieved durable remission and long-term survival, suggesting potential broad therapeutic applicability across risk categories
- Advancement Toward Phase II & Beyond: Data support progression to a phase II trial aimed at confirming CR, PFS, and OS, expanding to multi-center sites, and exploring combination strategies to enhance NK-cell persistence and functional potency
A dynamic opening discussion featuring CEOs and founders at the forefront of innate immunity and NK-cell innovation. This high-level session sets the tone for the meeting as industry leaders examine the current landscape, emerging scientific and commercial inflection points, and the path to translating innate immune breakthroughs into meaningful therapeutic impact. Through candid insights and forward-looking perspectives, the panel will outline the opportunities, challenges, and decisive moves that will shape the field over the next 3–5 years.
- The milestones that brought innate therapies to today’s inflection point
- What’s driving the next wave of NK and innate innovation
- Scientific and clinical hurdles that must be overcome
- Strategic priorities in a shifting funding and regulatory climate
- Commercial pathways and competitive positioning for the next era
